Keros Therapeutics (KROS) Net Income towards Common Stockholders (2019 - 2025)
Keros Therapeutics posted quarterly Net Income towards Common Stockholders of -$23.5 million for Q4 2025, up 49.03% year-on-year from -$15.7 million in Q4 2024, and down 222.27% on a QoQ basis from -$7.3 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$23.5 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 49.03% year-over-year to -$23.5 million; the trailing twelve-month figure through Dec 2025 stood at $87.0 million (up 146.44% YoY), and the FY2025 full-year result was $87.0 million, up 146.44% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$23.5 million, down from -$7.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $148.5 million in Q1 2025 and bottomed at -$53.0 million in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$28.5 million (2022), against an average of -$20.8 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders slumped 328.21%; it then jumped 444.32% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.9 million in 2021, then plunged by 328.21% to -$29.7 million in 2022, then plunged by 35.42% to -$40.2 million in 2023, then dropped by 14.37% to -$46.0 million in 2024, then jumped by 49.03% to -$23.5 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -23.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.46 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -30.70 Mn |
| Mar 31, 2025 | 148.45 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -40.24 Mn |
| Sep 30, 2023 | -39.44 Mn |
| Jun 30, 2023 | -37.51 Mn |
| Mar 31, 2023 | -35.80 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -6.94 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -15.62 Mn |
| Mar 31, 2021 | -15.89 Mn |
| Dec 31, 2020 | -9.66 Mn |
| Sep 30, 2020 | -12.04 Mn |
| Jun 30, 2020 | -10.96 Mn |
| Mar 31, 2020 | -12.70 Mn |
| Dec 31, 2019 | -3.20 Mn |
| Sep 30, 2019 | -4.00 Mn |
| Jun 30, 2019 | -3.30 Mn |
| Mar 31, 2019 | -3.63 Mn |